Predicting toxicity from radiotherapy after breast cancer surgery and reconstruction
Official title: Prospective Evaluation of a Predictive Toxicity Test Post Radiotherapy After Mastectomy With Immediate Implant Reconstruction
Run by Institut du Cancer de Montpellier - Val d'Aurelle · NCT04342546 · Data updated 2026-11-12
This study is testing a new test to see if it can help identify breast cancer patients who might experience severe side effects from radiation after surgery and reconstruction, so they can receive better care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 250 (estimated) |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | radiation |
| Locations | 9 sites (Dijon and 8 other locations) |
| Status | Recruiting |
| Started | December 11, 2020 |
| Main results expected | December 10, 2029 |
| Study ends | December 10, 2031 |
| Registry record updated | April 13, 2026 |
| Trial ID | NCT04342546 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include women aged 18 and older with histologically confirmed breast cancer who are undergoing mastectomy and are eligible for immediate breast reconstruction with implants.
✕Probably not a fit
Patients with inflammatory breast cancer, metastatic disease, or those requiring flap reconstruction will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the NovaGray RILA Breast® test's ability to predict the toxicity associated with radiotherapy following mastectomy and immediate breast implant reconstruction. It aims to identify patients at high risk for severe side effects from radiotherapy, which can negatively impact cosmetic outcomes and quality of life. By assessing T-CD8 lymphocyte apoptosis, the study seeks to personalize treatment strategies and potentially reduce unnecessary surgeries for low-risk patients. The goal is to improve patient care and outcomes in breast cancer treatment.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment plans that minimize the risk of severe side effects from radiotherapy in breast cancer patients.
How similar studies have gone: Other studies have shown promise in using predictive tests for radiotherapy toxicity, but this specific approach with the NovaGray RILA Breast® test is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Patients with histologically confirmed breast cancer with indication of mastectomy or surgery with mastectomy performed * Indication of wall chest radiation after mastectomy * Patient's agreement to receive or having had an immediate breast reconstruction by implant in one or two steps, with or without a dermal or synthetic matrix (depending on the habits of the center) * Performance Status 0-1 * Consent signed before any study procedure * Patient geographically accessible for follow-up * Affiliated to the French national social security system Exclusion Criteria: * Breast reconstruction with flap * Inflammatory breast cancer (cT4d) * Skin or parietal breast cancer (cT4 a, b or c) * Metastatic patients * Patients with bilateral breast cancer * History of homolateral breast cancer treated with radiotherapy * History of contralateral breast cancer * Pregnant or breastfeeding women * Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent * Participation in an interventional clinical study or planned participation during study up to 12 months post-radiotherapy
Where it's running
-
Centre Georges François Leclerc
Dijon, France Recruiting -
Centre Oscar Lambret
Lille, France Recruiting -
Centre Léon Bérard
Lyon, France Recruiting -
Institut Paoli Calmette
Marseille, France Recruiting -
Institut du Cancer de Montpellier
Montpellier, France Recruiting -
centre Antoine Lacassagne
Nice, France Recruiting
Show 3 more locations
-
Hôpital Tenon
Paris, France Recruiting -
Institut de Cancérologie de l'Ouest
Saint-Herblain, France Recruiting -
Institut Claudius Regaud
Toulouse, France Recruiting
Study contacts
- Study coordinator: Aurore MOUSSION
- Email: DRCI-icm105@icm.unicancer.fr
- Phone: 04 67 61 31 02
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.